<DOC>
	<DOCNO>NCT00834717</DOCNO>
	<brief_summary>The objective study evaluate comparative bioavailability granisetron hydrochloride 1 mg tablet ( Teva Pharmaceuticals USA ) Kytril® 1 mg tablet ( Roche , USA ) , single-dose health subject fast condition .</brief_summary>
	<brief_title>Granisetron 1 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Healthy , nonsmoking , male female subject , 18 year age old . BMI ≥ 19 ≤ 30 . No significant diseases clinically significant finding physical examination . No clinically significant abnormal laboratory value . No clinically significant finding 12lead electrocardiogram ( ECG ) . No clinically significant finding vital sign measurement . Be informed nature study give write consent prior receive study procedure . Negative : HIV . Hepatitis B surface antigen Hepatitis C antibody . Urine drug abuse test ( marijuana , amphetamine , barbiturate , cocaine , opiates , benzodiazepine methadone ) . Urine cotinine test . Serum HCG consistent pregnancy ( female ) . Females participate study : unable child ( e.g . postmenopausal , tubal ligation , hysterectomy ) OR willing remain abstinent [ engage sexual intercourse ] OR willing use effective method doublebarrier birth control [ partner use condom female use diaphragm , contraceptive sponge , spermicide IUD ] Females participate study pregnant and/or nonlactating . Known history presence clinically significant medical condition . Known suspected carcinoma . On special diet within 4 week prior drug administration ( e.g . liquid , protein , raw food diet ) . Participated another clinical trial receive investigational product within 30 day prior drug administration . Donated 250 mL blood within previous 30 day OR Donated 251 500 mL blood previous 45 day OR Donated 500 mL blood previous 56 day ( base Canadian Blood Services guideline blood donation ) . Females take oral transdermal hormonal contraceptive within 14 day precede period 1 dosing OR females take implanted injected hormonal contraceptive within 6 month prior period 1 dosing . Requirement nontopical medication ( prescription and/or overthecounter ) routine basis . Difficulty fast consume standard meal . Do tolerate venipuncture . Unable read sign ICF . Known history presence : Hypersensitivity idiosyncratic reaction granisetron hydrochloride and/or drug substance similar activity . Alcoholism within last 12 month . Drug dependence and/or substance abuse . Use tobacco nicotinecontaining product , within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>